Bausch Health Companies Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Bausch Health Companies Inc. (BHC) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $293.00 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-07-30
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $293.00M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $293.00M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $292.00M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $263.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed |
|---|---|---|
| 2026-06-30 | $293.00M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $293.00M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $292.00M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $263.00M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $303.00M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $339.00M 10-Q · filed 2026-04-30 | |
| 2024-12-31 | $359.00M 10-Q · filed 2026-07-30 | |
| 2024-09-30 | $285.00M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $269.00M 10-Q · filed 2025-07-31 | |
| 2024-03-31 | $281.00M 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $292.00M 10-K · filed 2026-02-19 | |
| 2023-09-30 | $299.00M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $248.00M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $269.00M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $241.00M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $224.00M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $225.00M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $236.00M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $241.00M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $244.00M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $280.00M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $313.00M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $328.00M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $312.00M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $316.00M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $312.00M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $316.00M 8-K · filed 2022-05-11 | |
| 2019-09-30 | $313.00M 10-Q · filed 2020-11-03 | |
| 2019-06-30 | $318.00M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $309.00M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $339.00M 8-K · filed 2021-05-04 | |
| 2018-09-30 | $336.00M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $364.00M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $378.00M 10-Q · filed 2019-05-06 | |
| 2017-12-31 | $387.00M 10-K · filed 2020-02-19 | |
| 2017-09-30 | $390.00M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $807.00M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $874.00M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $892.00M 10-K · filed 2019-02-20 | |
| 2015-12-31 | $1.16B 8-K · filed 2018-08-10 | $1.16B 10-K · filed 2016-04-29 |
| 2014-12-31 | $348.00M 10-K · filed 2017-03-01 | $308.80M 10-K · filed 2015-02-25 |
| 2013-12-31 | $355.80M 10-K · filed 2016-04-29 | $355.76M 10-K · filed 2014-02-28 |
| 2012-12-31 | $455.10M 10-K · filed 2015-02-25 | $455.08M 10-K · filed 2014-02-28 |
| 2011-12-31 | $420.08M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |